The gene PLA2G3 (group 3 secretory phospholipase A2) is mapped to human chromosome 22q12.2. The protein localizes in the cytosolic punctuate structures.
Synonyms: Anti-GIII sPLA2; Anti-Group 3 secretory phospholipase A2; Anti-Group III secretory phospholipase A2; Anti-Phosphatidylcholine 2-acylhydrolase GIII; Anti-sPLA2-III
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: PLA2G3 (group 3 secretory phospholipase A2) is a secretory phospholipase. It is involved in the release of cellular arachidonate (AA). PLA2G3 is reported as a negative regulator of ciliogenesis. Absence of PLA2G3 results in cells showing centrosome-concentrated recycling endosomes. In human neuronal system, it participates in xanthine/xanthine oxidase (X/XOD)-mediated apoptotic cell death. Polymorphism in PLA2G3 is linked with Alzheimer's disease (AD). The expression of PLA2G3 is deregulated in various malignant tissues.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC